What are RNA-therapeutics, and how will they revolutionise medicine? Julie Anderson answers these questions and tells us about CPI’s role in the industry.
The mRNA vaccines produced during the COVID-19 pandemic ushered in a new medical technology: RNA-based therapeutics. Thanks to that breakthrough success and advances in DNA sequencing and gene editing, the life science and pharmaceutical industries have embraced the wider possibilities of RNA technology.
In the race to combat COVID-19, mRNA vaccines were designed, tested and rolled out in record time to save millions of lives around the world. This was a landmark event that accelerated the development of RNA-based therapeutics, setting them up to revolutionise the way we treat health and disease.
To take advantage of this momentum and improve the health of more people, we need to improve funding for innovative research and find the right collaborators to scale up production and commercialisation. CPI can help navigate the unique challenges that come with manufacturing RNA-based therapeutics, as well as providing industry-leading training in this area.
